OptimizeRx Corporation
OPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $92 | $72 | $62 | $61 |
| % Growth | 28.8% | 14.5% | 1.9% | – |
| Cost of Goods Sold | $33 | $29 | $23 | $26 |
| Gross Profit | $59 | $43 | $39 | $36 |
| % Margin | 64.5% | 60% | 62.4% | 58.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $61 | $58 | $49 | $28 |
| SG&A Expenses | $61 | $58 | $49 | $33 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $6 |
| Other Operating Expenses | $12 | $11 | $2 | $2 |
| Operating Expenses | $73 | $69 | $51 | $35 |
| Operating Income | -$14 | -$26 | -$12 | $0 |
| % Margin | -14.9% | -36.9% | -19.7% | 0.6% |
| Other Income/Exp. Net | -$6 | $1 | $1 | $0 |
| Pre-Tax Income | -$19 | -$25 | -$11 | $0 |
| Tax Expense | $1 | -$8 | $0 | $0 |
| Net Income | -$20 | -$18 | -$11 | $0 |
| % Margin | -21.8% | -24.6% | -18.3% | 0.6% |
| EPS | -1.1 | -1.03 | -0.64 | 0.022 |
| % Growth | -6.8% | -60.9% | -3,022.4% | – |
| EPS Diluted | -1.1 | -1.03 | -0.64 | 0.021 |
| Weighted Avg Shares Out | 18 | 17 | 18 | 17 |
| Weighted Avg Shares Out Dil | 18 | 17 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $1 | $0 |
| Interest Expense | $6 | $1 | $0 | $0 |
| Depreciation & Amortization | $4 | $2 | $2 | $2 |
| EBITDA | -$9 | -$21 | -$9 | $2 |
| % Margin | -9.7% | -29.8% | -15.1% | 3.8% |